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Abstract
Background: The advent of immune checkpoint inhibitors (ICIs) has significantly improved the prognosis of patients
with advanced malignancies. On the other hand, these drugs might cause immune-related adverse events (irAEs)
including endocrinopathies and nephropathies. Thyroid dysfunction is one of the most common irAEs. For ICIs-induced
nephropathies, most cases are due to tubulointerstitial nephritis, which might require steroid treatment. Here, we
report a patient with non-small cell lung cancer treated with ICI who developed increased serum creatinine (s-Cr) levels
due to ICIs-induced hypothyroidism.
Case presentation: A 57-year-old Asian man with refractory non-small cell lung cancer under ICIs therapy
(pembrolizumab, an anti-programmed cell death-1 monoclonal antibody) developed increased s-Cr levels 5 months
after the pembrolizumab initiation. His laboratory data, renal biopsy, and Gallium-67 scintigraphy findings denied
pembrolizumab-induced tubulointerstitial nephritis. His renal function was correlated with thyroid function. Despite the
increase of s-Cr levels, serum cystatin C levels were normal, which could be explained by the hypothyroidism.
Levothyroxine treatment improved renal function as well as thyroid function. Then pembrolizumab was resumed, and
both his thyroid and renal function remained normal level. Ultimately, we concluded that the increased s-Cr levels
were caused by pembrolizumab-induced hypothyroidism.
Conclusion: All clinicians involved in ICI treatment need to recognize the possible increase in s-Cr levels caused by
ICIs-induced hypothyroidism, and we propose monitoring serum cystatin C levels to differentiate ICIs-induced
hypothyroidism from tubulointerstitial nephritis before invasive renal biopsies or steroid treatment, which are
recommended by the prescribing information for pembrolizumab, are performed.
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Background
Immune checkpoint inhibitors (ICIs) have been developed,
and the advent of ICIs significantly improved the prognosis
of patients with advanced malignancies. However, these
drugs have been reported to lead to immune-related
adverse events (irAEs), including endocrinopathies and
nephropathies. Renal dysfunction occurs in 0.3% of the
patients under the treatment of pembrolizumab, an anti-
programmed cell death-1 monoclonal antibody [1], and
most reported cases are due to tubulointerstitial nephritis
[2]. Here we describe a case of reversible increased serum
creatinine (s-Cr) levels due to hypothyroidism caused by
pembrolizumab.
Case presentation
A 57-year-old Asian man was diagnosed as lung adeno-
carcinoma with several bone metastasis (non-small cell
lung cancer (NSCLC), T1cN0M1c stage IVB, epidermal
growth factor receptor (EGFR): negative, anaplastic
lymphoma kinase (ALK): negative, programmed death
ligand 1 (PDL1) tumor proportion score: 5%, Fig. 1a-c),
and he was initially treated with cisplatin and
pemetrexed for 4 months, followed by 2nd line pembroli-
zumab treatment (200mg/3 weeks). Although his lung
tumor decreased in size, levels of s-Cr gradually increased
(from 0.88mg/dl to 1.49mg/dl) and the estimated glom-
erular filtration rate (eGFR) decreased (from 69.9ml/min/
1.73m2 to 39.3ml/min/1.73m2) within 5 months after the
pembrolizumab initiation (Fig. 2). According to the
Keytruda® prescribing information [3], pembrolizumab
was discontinued, and he was admitted to our hospital. At
admission, his height was 172.8 cm, his body weight was
88.1 kg, and his body mass index was 29.4 kg/m2. His body
temperature was 36.4 °C, his pulse was 67 per minute, and
his blood pressure was 144/92mmHg. There were no epi-
sodes of hypotension at home or office visit. Electrocar-
diogram and computed tomography (CT) analyses denied
arrhythmia, myocarditis or pericarditis, which could influ-
ence renal perfusion. There was no elevation in the C-
reactive protein (CRP) levels. Despite the increase in s-Cr
levels, serum cystatin C (s-cystatin C) levels were within
the normal range (0.81 mg/L). 24-h creatinine clearance
(Ccr) was 62.8ml/min and urine creatinine was 1.8 g/day.
Antinuclear and antineutrophil antibodies were negative.
Fig. 1 Imaging findings of lung CT and pathological findings of renal biopsy. a Positron emission tomography (PET)-CT picture showing a
2.5 cm-sized nodule on left upper lobe (arrow). b-c PET-CT pictures showing bone metastases on his right 7th rib and 11th thoracic
vertebrae (arrows). d Light microscopy picture showing normal glomerular morphology without any evidences of tubulointerstitial
abnormalities (periodic acid-methenamine-silver staining, × 40)
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Urinalysis showed neither hematuria nor proteinuria nor
an increase in urinary β2-microglobulin (β2MG) and N-
acetyl-β-glucosaminidase (NAG) levels. Gallium-67 scin-
tigraphy showed no uptake in the kidneys. A renal biopsy
was performed, which revealed neither glomerular nor
tubulointerstitial abnormalities (Fig. 1d), thus denying
pembrolizumab-induced tubulointerstitial nephritis and
glomerulonephritis.
Retrospective evaluations revealed that the patient had
developed asymptomatic hyperthyroidism with anti-
thyroglobulin antibodies (23 IU/mL) and anti-TSH
receptor antibodies (TRAb) (6.31 U/l) 3 months after the
initiation of pembrolizumab, which was followed by
asymptomatic hypothyroidism without adrenal insuffi-
ciency (Fig. 2). In summary, we diagnosed the patient
with pembrolizumab-induced painless thyroiditis. Since
the increase in s-Cr levels paralleled the decline in free
T4 (fT4) levels, we suspected an association between
hypothyroidism and increased s-Cr levels. Levothyroxine
at a dose of 25 μg daily was prescribed and gradually in-
creased. Levothyroxine treatment improved thyroid
function tests as well as s-Cr levels, while the levels of s-
cystatin C were elevated. 24-h Ccr after the improve-
ment of increased s-Cr levels (s-Cr: 1.00 mg/dl, eGFR:
61.5 ml/min/1.73m2) was 50.7 ml/min and urine creatin-
ine was 1.11 g/day. Without any abnormalities on renal
histology in renal biopsy or any signs of other causes of
renal dysfunction, such as hypotension and cargiological
abnormalities, we concluded that the increased s-Cr
levels were most likely caused by the rapid decline of
thyroid function during the transition from hyperthy-
roidism into hypothyroidism induced by pembrolizu-
mab. Pembrolizumab was resumed, and the patient’s
thyroid and renal function remained normal (Fig. 2).
Discussion and conclusions
This is the first case of reversible increased s-Cr levels
caused by ICI-induced hypothyroidism. Pembrolizumab
is a humanized monoclonal anti-PD1 antibody that in-
duces an immune response against tumor tissues. It has
been successful in inducing remission in patients with se-
vere metastatic disease, who are often refractory to other
chemotherapeutic agents. In refractory NSCLC, pembroli-
zumab prolongs overall survival and progression-free sur-
vival [3]. However, irAEs occur in 20% of patients on
pembrolizumab [4]. One of the most frequent irAEs caused
by pembrolizumab is thyroid disorders (hypothyroidism,
8%; hyperthyroidism, 6%) [4]. It was reported that nephritis
occurred in 9 (0.3%) of 2799 patients receiving pembrolizu-
mab, including grade 2 (0.1%), grade 3 (0.1%), and grade 4
(< 0.1%) nephritis [1]. In the majority of the cases, renal
dysfunction under pembrolizumab treatment is due to
tubulointerstitial nephritis [2]. Therefore, the cessation of
pembrolizumab, renal biopsies, and steroid treatment
(prednisolone 1–2mg/kg/day) are recommended in cases
of grade 2-4 renal failure in the Common Termin-
ology Criteria for Adverse Events (CTCAE) [1]. How-
ever, in our case, careful evaluation, including renal
biopsy, denied pembrolizumab-induced tubulointersti-
tial nephritis and revealed that pembrolizumab may
Fig. 2 Clinical course. Renal and thyroid function tests after the first usage of pembrolizumab
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have caused hypothyroidism-related increase in s-Cr
levels, which was able to be resolved with levothyrox-
ine treatment; thus, neither steroid therapies nor ces-
sions of pembrolizumab were required.
There is accumulating evidence showing a strong cor-
relation between changes in thyroid status and changes
in renal function [5]. It has been reported that s-Cr
levels decrease (− 17.6%) in hyperthyroidism compared
with those seen with normal thyroid function, whereas
an elevation in s-Cr levels is seen in hypothyroidism
compared with that seen with normal thyroid function
(+ 11%) [6]. In addition, a recent study indicated a
significant decline in eGFR after patients with hyperthy-
roidism became euthyroid, suggesting that hyperthyroid-
ism might mask mild renal failure [7]. It has also been
reported that eGFR declines in 55% of adults with
hypothyroidism, and thyroid hormone replacement usu-
ally resolves renal dysfunction [8, 9]. Although the de-
tailed mechanisms by which hypothyroidism causes
declines in eGFR are still unclear, it is suggested that
hypothyroidism might decrease renal function in mul-
tiple mechanisms. These include decreased kidney mass
[10], reduced renal perfusion pressure because of de-
creased cardiac output and increased vascular resistance
[11–13], reduced sensitivity to the body’s sympathetic
drive and renin-angiotensin-aldosterone system activity
[14], and possible rhabdomyolysis [15]. In addition, it
has also been reported that increased s-Cr levels under
hypothyroidism might be associated with increased cir-
culating Cr, suggesting hypothyroidism might increase s-
Cr levels independent of GFR. These mechanisms in-
clude increased release of Cr from muscle tissue due to
myopathy and rhabdomyolysis [16], and increased con-
version from creatine into creatinine [17]. Indeed, in our
case, re-evaluation of renal function revealed no increase
in 24-h Ccr after the levothyroxine treatment despite the
apparent improvement in s-Cr levels. In addition, a de-
crease in urine Cr after the levothyroxine treatment
(from 1.8 g/day to 1.11 g/day) was observed. These ob-
servations suggest that increased s-Cr levels under
hypothyroidism might be mainly due to the increased Cr
supply rather than due to decreased GFR. Further study
is required to uncover the exact mechanisms of in-
creased s-Cr levels under hypothyroidism.
In contrast to the increase in s-Cr levels, the levels of s-
cystatin C levels normally decrease under hypothyroidism
[18]. It has been reported that s-cystatin C levels decline
in hypothyroidism due to reduced production, consequent
to reduced cellular metabolism [18], and this result is dif-
ferent from that seen with other causes of renal dysfunc-
tion. Indeed, in our case, s-cystatin C levels were within
the normal range despite the increased s-Cr level on ad-
mission, and levothyroxine treatment reversed the in-
crease in s-Cr levels while it elevated s-cystatin C levels.
These findings are compatible with hypothyroidism-
induced increase in s-Cr levels. Importantly, both tubu-
lointerstitial nephritis and hypothyroidism-induced in-
crease in s-Cr levels are unlikely to show apparent
proteinuria or hematuria; Thus, these two different kinds
of pathologies are difficult to differentiate by urinalysis.
Therefore, monitoring both s-Cr and s-cystatin C levels
might help us differentiate the causes of increased s-Cr
levels.
Immune-related endocrine toxicities, including thyroid
dysfunction, are usually irreversible. Interestingly, overall
survival with pembrolizumab was significantly higher in
subjects who developed thyroid dysfunction under pem-
brolizumab treatment than those who did not develop
thyroid dysfunction (hazard ratio, 0.29; 95% confidence
interval (CI) 0.09–0.94; p = 0.04) [8], suggesting these pa-
tients might not need to stop permbrolizumab treatment
but rather could continue treatment with levothyroxine.
Therefore, hypothyroidism during pembrolizumab treat-
ment needs to be recognized quickly and to be treated
appropriately so that patients can keep using pembrolizu-
mab and prolong their overall survival. Considering the
high frequency of pembrolizumab-induced hypothyroidism,
our case is unlikely to be rare, and more similar cases could
appear. The number of cases might be underestimated be-
cause some cases might be misdiagnosed as tubulointersti-
tial nephritis and subjected to steroid treatment. Since not
so many clinicians are aware that hypothyroidism may
cause increased s-Cr levels, it is urgent to highlight possible
hypothyroidism-caused increase in s-Cr levels, which might
be reversed with levothyroxine treatment. Nevertheless,
it may take a relatively long time until s-Cr levels re-
turn to baseline with the levothyroxine treatment under
hypothyroidism-induced increase in s-Cr levels. Indeed,
it took approximately 2 months in our case. Since the
delay of steroid treatment in tubulointerstitial nephritis
could lead to irreversible renal damage, renal biopsy is
still am important option to differentiate these causes
when physicians are not confident in ruling out the
possibility of tubulointerstitial nephritis.
In conclusion, all clinicians involved in ICI treatment
need to recognize possible hypothyroidism-caused in-
crease in s-Cr levels, which can be reversed with
levothyroxine treatment. We propose monitoring s-
cystatin C levels routinely as well as thyroid function
under ICI treatment to differentiate hypothyroidism-
related increase in s-Cr levels from tubulointerstitial
nephritis before renal biopsies or steroid treatment are
performed.
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